EMA Discusses Pivotal Role Of RWE For Six Drugs
Executive Summary
The European Medicines Agency explains how it used real-word evidence during recent deliberations for six products.
You may also be interested in...
EMA Lays Out Plans For Routine Use Of Real-World Evidence
A panel of regulators overseeing the implementation of several big data projects within the EU medicines network has given details of real-world evidence integration pilots to be undertaken next year by various European Medicines Agency scientific committees.
Disappointing End For MolMed’s Zalmoxis Cell Therapy In EU
MolMed decided to the withdraw the drug's conditional marketing authorization after Phase III clinical trial results showed that the drug offered no benefit on disease-free survival.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.